Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Exclusion Criteria

• •2. Previous treatment with VEGF or EGFR inhibitors.
• •3. Cytotoxic chemotherapy, immunotherapy or radiotherapy \<=4 weeks prior to study entry.
• •4. History or known presence of central nervous system (CNS) metastases.
• •5. Patients who have had a major surgical procedure (not including mediastinoscopy), open biopsy, or significant traumatic injury \<=4 weeks prior to beginning treatment.
• •6. Female patients who are pregnant or lactating.
• •7. History of hypersensitivity to active or inactive excipients of any component of treatment (bevacizumab, sandostatin, and/or pertuzumab).
• •8. Patients with proteinuria at screening as demonstrated by urine dipstick for proteinuria \>=2+ (patients discovered to have \>=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection, and must demonstrate \<=1 g of protein/24 hours to be eligible).
• •9. Patients with a serious non-healing wound, active ulcer, or untreated bone fracture.
• •10. Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).
• •11. Patients with history of hematemesis or hemoptysis (defined as having bright red blood of ½ teaspoon or more per episode) \<=1 month prior to study enrollment.
• •12. History of myocardial infarction or unstable angina \<=6 months prior to beginning treatment.
• •13. Inadequately controlled hypertension (defined as systolic blood pressure \>150 mmHg and /or diastolic blood pressure \>100 mmHg while on antihypertensive medications). Initiation of antihypertensive agents is permitted provided adequate control is documented at least 1 week prior to Day of study treatment.
• •14. New York Heart Association (NYHA) grade II or greater congestive
• •heart failure (CHF).
• •15. Serious cardiac arrhythmia requiring medication.
• •16. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair, or recent peripheral arterial thrombosis) \<=6 months prior to Day 1 of treatment.
• •17. History of stroke or transient ischemic attack \<=6 months prior to beginning treatment.
• •18. Any prior history of hypertensive crisis or hypertensive encephalopathy.
• •19. History of abdominal fistula or gastrointestinal perforation \<=6 months prior to Day 1 of beginning treatment.
• •20. Concurrent severe, intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
• •21. Any known positive test for human immunodeficiency virus, hepatitis C virus or acute or chronic hepatitis B infection.
• •22. Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study.
• •23. Use of any non-approved or investigational agent \<=28 days prior to administration of the first dose of study drug. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.
• •24. Past or current history of neoplasm other than the entry diagnosis with the exception of treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancers cured by local therapy alone and a DFS \>=5 years.
• •25. Infection requiring IV antibiotics.